Two intracoronary doses of basic fibroblast growth factor enhance collateral blood flow in dogs  by Rajanayagam, Shamini et al.
5 
U ~ 
D" 
A 
Y 
P 
0 
S 
T 
E 
R 
36A ABSTRACTS-Poster JACC February 1996 
haamatoc~ w~e cell count ONCC)) in 64 paUents (43 male; mean age 63.2 
years, s.d. 8.9) admitted with acute stroke (ictus onset < 12 hours). Levels 
of these madrms and blood pressures (BPs, mmHg) were compared to 21 
healthy controls (age 6t .5 years, s.d. 11.7). Our results are shown in the table. 
There were no significant differences in these markers and BPs between 
patients who were alive or dead (n = 13) aner 6 months followup. Plasma 
viso0sity was s in i f~  cormtatad to fibrinogen (r = 0,5,p < 0.001) and vWf 
(r = 0.3, p = 0.04). Stepwise mul~ple regression analysis demonstrated that 
faxinogen a.d diasfoli~ UPs were predictors for plasma viscosity (p = 0,018). 
Onty the WGC level was a pre~ctor for flbrinogen levels (p = 0.03). There 
were no s'~nificaat pmo'ictsrs for vWt and P-selectin levels. Despite eady 
pmsentatfon (< 12 Itours) patients with acute stroke have haemorhnolngical 
abhorrences (l~odnogen, WCG and plasma viscosity), ptatofot dysfunoUan 
(with raised P-seio~Jn) and endothelial dysfunction (with high vWf), Tilase 
abnormalities may act synergistically inthe p~thogenasis ofacute stroke and 
its complications, 
PHARMACOLOGY-  BASIC 
~ T w o  Intracoronary Ooses of Basic Fibroblast 
Growth Factor Enhance Collateral Blood ROw in 
oogs 
Shennini Rajanayagam, M~e Sbou, Venogepal Thimmudi, Everett Hedge, 
Daisy F:. Lazarens, Amhed A. Quyyend, Stephen E, Epstein, Ellis F. Unger. 
~wology Branch, NHLBI, Bethasda, MD 
Bask= flbreblast growth factor (bFGF), an angiogenic growth factor, is cur- 
rently the subject of a Phase I clinical thai in pts wiih ischemic heart disease 
(IHD). In a Canine model of single vessel coronary occlusion, we previously 
demonstrated that bFGF enhances collateral blood flow (CBF) when given 
as a daily I.C, bolus for 4 weeks, or as a deJly left atrial bolus for 7 days; 
however, these schedules and mutes of administration would not be practl~ 
cal in pts with IHD. To establish a feasible mute of drug delivery and to limit 
potential systemic toxicity, we determined whether injection of bFGF into the 
left main coronary artoly would enhance CBR A second aim was to astab. 
fish the minimum effective course of bFGF b'eatment. Dogs were subjected 
to amemkHnducod occlusion of the left circumflex nsmnary adew. Subse- 
qUeotly, the dogs undelwent cardiac cathatedza~on a d were randomized to 
receive bFGF 0.1 mg/kg as a bolus into the left main coronmy artery twice 
(14 and 16 days after amereid placement, n = 10) or once (day 16, n = 8), 
A control group received the vehicle (n = 10), CBF was assessed dudng 
maximal coronaq/vasodilatation with radiolsheled microsphems on day 33, 
Maximal CBF in dogs ~ received bFGF twice was 2.39 :E 0.09 ml/min/g, 
exceeding that of control dogs by 39=/0 (1.72 :E 0.13 ml/miNg, mean :E SE; 
P < 0.0005), Dogs that received a single dose Of bFGF had an intermediate 
flow (2.10 :E 0.21 ), statistically indistinguishable from the other gmupe. Thus, 
two doses of bFGF administered into the left main coronary anery were suf~ 
fioient to improve CBF, an inteprention that is feasible in pts with IHD, These 
data provide the basis for a tdal of inIJracomnaty bFGF in pts with IHD. 
Effects of Mao.1 Inhibitor on Hemostasis During 
Myocardial Stunning in Swine 
Victor L. Sembrusny, Andrew R, Shustov, Paul A. Gurhel, William 
R. Herzog. University of Maryland, Baltimore, MD 
The impodant role of hemestatic disorders has been Increasingly recog- 
nized in patients with myocardial ischemia. NPG 15669 is a member of the 
leumadins, and inhibits leukocyte adhesion to the endothniium by blockage 
of Mac-1 upregulalion. The effects of NPC 15669 supplementation on the 
hemostatfo profile dedng myocazdial stunning (MS) are poorly understood. 
Thus, the puq~ese of this project was tO link potential changes in hamestalJc 
profile with NPC 15669 therapy dudng mild MS in in v/vo anin~ ntodel. 
Twelve opeo<dlasted Yorkshire swine underwent LAD occlusion for 8 
minutes followed by 90 minutes of reperfusion. Blood samples were obtained 
at baseline, at 4 and at 8 minutes of OcClusion, and at 60 ~',d 90 minutes 
of reped~Jsion, NPC 15669 (10 mg/kg loading dose followed by constant 
infusion at 6 rag/k9 -1/11 -t) was administered in 6 animals; another 6 swine 
received saline end served as conlmls. Coneenlmtions of antithrombth-III 
(AT-Ill), Protein C, total Protein S, ftb~ne~n, endothniin-t lET-l), as well 
as the stable metabulitss of thmmboxane (TxB~) and prostacydin (6-keto- 
PGFI=), were measured in the systemic cin~l~ion, Treatment with NPC 
15669 was assedalsd with diminished ETol (37,4%), 6-kato-PGFla (47.1%) 
levels and inornased fibmno~in (77.6%) concentrations during MS, There 
were no changes in the plasma cenceatrations of TxB.z, total protein S, 
protein C and AT-Ill in NPC 15669 group when compared with controls. 
Mild MS ts as~sociatsd with sobstantial dynamio changes in the hanlestatfo 
profile. NPC 15669 administration i  a swine model of MS alfe¢ls spenif'¢ 
hemostatls parameters. This data provl~s lrong support for the involvement 
of cellular ~ ls rns  and endothelial dyshmc~on in the petbogenesls of 
MS. The ability of the drug to modulate hemostasis may have implications 
for the use of lsumedins in cardiovascular drseese. 
PHARMACOLOGY-  CL IN ICAL  
Effect of Calcium Channel Blockers on the 
Incidence of Myocardial Infarction in Patients 
With Left Ventdcular Dysfunction 
John B. Kostis, Alan C, Wilson, Nora M. Cosgn)ve, Clifton R, lacy, from the 
UMDNJ-Robert Wood JohnSon Medical SchOOl Clinical Center Based on 
the SOLVD Database. UMDNURobert Wood Johnson Medical School, New 
Brunswick, NJ 
Recent studies have suggested an increased risk of myocardial infarction (MI) 
in patients on calcium channel blockers (CCB). We evaluated the effect of 
CCB on fatal and non-fatal MI in 6797 patientS with left ventricular dysfunction 
(LVD, EF < 35%) in the Studies Of Left Ventdcular DysfuncUan (SOLVD). 
During 40 months average follow-up, fatal or non.fatal MI occurred in 11.5% 
of the 845 patientS on CCB dudng follow-up versus 7.5% of the 255t patients 
not on CCB (,0 ~= 0.001, O.R. 1.6195% Cl 1.24-2,07) in the enalupdl group; 
and in 14.4% of the 874 patients on CCB versus 9,3% of the 2527 patients not 
on CCB (p = 0.001, O,R. 1.64; CI 1.30-2.06) in the placebo group, 
By multivariate Cox regression analysis, adjus~ng for 29 variables descch- 
log demographics, Gomorblddy, e~oiooy and sovedty of LVD, head failure, 
and cancomitont drug use, CCB use dudng follOw-up was an independent 
predictor of increased dsk (R.R. 1.37; CI 1.14-1.63), 
The increased dsk associated with CCB was also observed when the 
combined endpoint of MI, cardiac death, or hospitalization for angina was 
considered. The incrcased MI risk was obsen/ed whether CCB were used 
both at baseline and follow-up or only at follOw-up. In addition, the risk was 
higher when the mean follow-up heart rate Of pa~ents on CCB was higher 
than the median follow-up rate of patients on CCB (74 beats/minoto). 
In contrast~ using the same database and analysis, beta 104od,,m use was 
assodated with a lower rate of fatal or non-fatal MI (multivariate Cox R.R. 
0.80; Cl 0.61-1.05). 
In this relmspactive analysis of patients with LVD, CCB use was associated 
with significantly increased risk of MI. 
_Ls Th. mmboly~c Therapy Most Effective When 
P.noogenoas Fibdnolysis Is Oeficient? 
Felidta Aedreofti, Gerard Dootjewaa~, Cornalis Kluft, Gilbert R. Thompson, 
Anne Kehely, David R. HaCkett, Graham J. Davies, AtlJlio M&sed. C, at~t/c 
University, Rome. Italy and Hammersmith Hospital, London, UK 
Thmmbi that form as a result of defective endogenous Iti0dnolysis may be 
most sensitive to thmmbolylic agents, Impaired flbfinolytic activity has been 
aSSociated with low plasma levels of single.d~ln urokinase (scu-PA), raised 
I~lxotoin(a) [Lp(a)] and, paradoxically, high t-PA enSgen. 
We invest.~gated the relation between endogenous fibdrmlytic factors on 
admission and subsequent efficacy of thrombolytio therapy in 51 patients 
with acute myocardial infarction (AMI) boated within 6 h of symptoms with 
intravenous rt-PA (20-60 MU) and hepadn, Pm-traatment plasma concen- 
trations of Lp(a) (mg/dl), t-PA antigen lug/L) and urokinase (U-PA, ug/L) were 
measured by ELISAs and of scu-PA lug/L) by bioimmunoassay. A coronary 
artedogram was performed 90 min after the start of lytic therapy. Pedusion 
of the infamt-artsry was defined as TIMI grade 3, 
At 90 rain, a TIMI 3 infarot-erfory was found in 27 pts, The perfosed v,3 
o4:~uded-artew pts did not differ significantly in age, sex, smoking stslus, 
delay to treatment, ime of day of therapy Or rt-PA dose at 90 min. Plasma 
factors (median and interquariffes) were: 
Lp(a) t-PA scu.PA u-PA 
Perfused 16 (11-~2) 26 (17-~) t.9 (1.6--2,1) 2,7 (P-2-,3) 
Occluded 9 (5-27) 15 (10-P.1) P,l(1.g-2.6) 2.6 (2.4-2.8) 
p value 0,02 0.003 0.03 0,38 
Thus, in patients with AMI receiving rt-PA, early coronary mperfusion, cony 
pared with persistent occlusion, is associat~l with higher plasma Lp(a) and 
t-PA antigen levels and lower plasma scu-PA on admission. Phannacotsgical 
doses of rt*PA thus appear most effective when naturalflbdnatysls i def'cteot. 
~ Effect of ProstaWclin in~s ion  as a Treatment of 
Pulmonary Hype~ns ion  
A. Yazdeni Butt, George Cremona, Unda Sharpleo, Arlene McMohan, Tim 
W. Hlgenheftam, Papwodll Hospital, C, ambddge, England, U.K. 
We have examined the alfect of continuous infusion of prostacyclin (PGI~) 
